Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Takayasu Arteritis
NCT07325357Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of pirfenidone in Takayasu arteritis (TAK), sponsored by Zhongshan Hospital, Fudan University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
pirfenidone
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on NCT07325357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07325357.